Business Overview
Lord's Mark Industries Limited is a BSE-listed conglomerate with a 27-year legacy operating across MedTech, Renewable Energy, and Healthcare diagnostics. The company has transformed from paper trading to becoming an integrated MedTech and sustainable infrastructure company.
Investment Highlights
- Technology-led innovation with strong execution capabilities and long-term growth opportunities
- High-margin Healthcare segment (IVD, MedTech, Dialysis, Genomics) synergistic with scalable Renewable Infrastructure
- 30+ registered brands, 139 trademarks, exclusive IIT-Bombay & BARC licenses, CDSCO/CE approvals
- ₹3,000+ crore renewable energy order pipeline backed by marquee PSU and government relationships
- 700+ distributors, 200+ enterprise clients across 15+ states with growing SAARC and US export footprint
- Cricket icon Rahul Dravid serves as Brand Ambassador across MedTech, Pathology and Genomics segments
Financial Projections FY25-FY29
The company provided detailed financial forecasts:
- Revenue expected to grow 3.6x from ₹710 Cr in FY25 to ₹2,586 Cr by FY29
- EBITDA projected to increase 8.7x from ₹75 Cr to ₹650.36 Cr
- EBITDA margin expansion from 10.5% to 25.1% (+1460 bps)
- Adjusted PAT expected to grow nearly 10x from ₹40 Cr to ₹422 Cr
- Diluted EPS projected to increase from ₹1.07 to ₹9.50
- ROCE improvement from 12% to 25% (+1300 bps)
Segment-wise Revenue Breakdown (FY25 → FY29E)
- IVD: ₹334 Cr → ₹1,117 Cr (Largest segment by FY29, includes diagnostics, Biochemistry, Analyzer and Reagents)
- Renalcare (Dialysis): Launches FY27 at ₹62 Cr → ₹294 Cr by FY29 (EBITDA margin 25-50% - highest in portfolio)
- Medtech: ₹8 Cr (FY27) → ₹175 Cr (FY29) at ~34% EBITDA margin
- Lighting & Renewables: Combined ₹301 Cr → ₹1000 Cr (Lighting: ₹225 Cr → ₹457 Cr; Solar/Renewables: ₹76 Cr → ₹543 Cr)
Healthcare (IVD+MedTech+Dialysis) is expected to contribute more than half of all incremental revenue growth over the forecast period.
MedTech Innovations and IP
Renalyx AI Dialysis (85% owned subsidiary)
- India's first indigenous AI-based Dialysis Machine with European CE Certification
- Patented technology with 7 years of clinical trials
- Reduces water use by 50%+ versus conventional machines
- Cloud-connected platform with Renal Command Center for real-time CKD tracking
- Painless dialysis treatment capability
AI Breast Screening (C-MET collaboration)
- Non-radiative, painless thermal mapping wearable for early detection
- Enables rural screening without hospital infrastructure
Oncodiagnoscope (BARC collaboration)
- Portable optical spectroscopy device for oral cancer detection
- 20-minute non-invasive result versus multi-week biopsy cycles
- Trialled on 12,000+ patients including at Tata Cancer Hospital
Strategic Partnerships and Licenses
- Exclusive license for point-of-care smartphone Sickle Cell diagnostics from IIT Bombay
- Exclusive technology transfer for Oncodiagnoscope oral cancer detection from BARC
- AI-powered, radiation-free Breast Cancer Screening wearable from C-MET, Thrissur
- Multiplex PCR for Myeloid Leukemia (AML-M2) from BITS Pilani
- Partnership with MapMyGenome for making genome testing accessible in India
- Ministry of Tribal Affairs collaboration for sickle cell screening across tribal communities
- Distribution and technology partnerships with Philips/Cipla/Braithwaite across Solar, Lighting and Healthcare
Manufacturing Capabilities
- In-house facility with single-roof production of rapid kits, reagents and analysers
- Only company in India with CDSCO scope for manufacturing Rapid, Biochemistry, Serology & Analyzer machines under one roof
- Gross margin profile: ~62% IVD, ~45% MedTech devices, ~12% Solar EPC (Company estimates)
Recent Regulatory Milestones
- ICMR approval for Sickle Cell and Genome Testing
- Approval to manufacture veterinary blood-testing machines
- Only India licence to manufacture Rapid, Biochemistry, Serology & Analyzer machines under one roof
- In-house manufacturing of blood test machines started
- Test licence received for cancer diagnosis
- Rudo Joint Pain Relief Oil launched (Surgical Division)
- Surgical Division received US FDA approval
Global Expansion
- United States: $1,000,000 maiden order for Contactless Remote Patient Monitoring (RPM) and AI Early Warning Systems (EWS)
- ISO 13485:2016, HIPAA and IEC 60601 compliant products
- SAARC: targeted diagnostic infrastructure deployment across Sri Lanka, Bangladesh and Nepal
- GCC & EU: strategic dialogues initiated at Davos 2024 for MedTech distribution hubs in UAE and GCC markets
Government Projects and Order Pipeline
- Current secured order book of ~₹2,000 Cr from UPNEDA, BREDA, EESL, APDCL, Railways, Defence and Navy
- Broader ₹3,000+ Cr pipeline
- Only firm holding design formula for all Indian Navy warships' lighting; lit aircraft carrier INS Vikramaditya
- Committed to 500 MW of solar capacity over 7 years, with 100 MW+ already secured for next two years
- Key GoI programmes: SAUBHAGYA (UPNEDA-UP, APDCL-Assam), Household Electrification (UPNEDA-UP), rural electrification of Bihar & Jharkhand via EESL
Growth Drivers
- PM Surya Ghar: ₹75,000 Cr budget for residential solar
- National Solar Mission targets 500 GW capacity by 2030
- 70% of Indian deaths trace to noncommunicable diseases
- 70-80% of medical devices in India are imported - substitution opportunity
- National Sickle Cell Elimination Mission targets 278 districts by 2047
Market Opportunity
- Indian MedTech: $11Bn→$50Bn (2022-30, 20.8% CAGR)
- Diagnostics: $16.2Bn→$43.5Bn (2023-32, 11.6% CAGR)
- Global Sickle Cell Treatment Market: $3.32Bn→$6.11Bn (2024-29, 12.9% CAGR)
- In Vitro Diagnostics (India): $1.91Bn→$2.27Bn (2024-28, 4.4% CAGR)
- Genome Testing (India): $0.4Bn→$1.7Bn (2024-30, 26.8% CAGR)
- Dialysis Machine Market (India): $5Bn→$11.3Bn (2024-33, 8.83% CAGR)
ESG Initiatives
- Targeting Net-Zero carbon emissions across operations by 2035
- 500+ MW planned solar capacity supporting grid decarbonisation
- Renalyx dialysis saves 50%+ water per session vs. traditional units
- Partnered with Ministry of Tribal Affairs to screen underserved tribal populations for Sickle Cell anaemia
- Deploying e-Smart Clinics to bring diagnostics to remote and rural locations
- BSE-listed entity adhering to SEBI Listing Obligations and Disclosure Requirements (LODR)
Growth Roadmap 2030
- FY 2026-27: Listing on NSE, global footprint in EU/USA/GCC, full-fledged R&D team, FPO/Preferential Allotment - ₹500 Crs
- FY 2027-28: Whole-time manufacturing unit for Medtech; Reach 2,000 pathology labs and 1,000 Renal Care Units; execute IVD/MedTech demerger
- FY 2028-29: Cross ₹5,000 Cr consolidated group revenue
- FY 2030: Full operational presence across US, EU, GCC and SAARC; established as leading Indian MedTech conglomerate
Risk Factors
- Regulatory approval timelines for new device approvals (CDSCO/US FDA/CE)
- Government payment cycles for PSU/state receivables
- Execution & scale-up risk for new manufacturing capacity and clinic rollout
- Competitive intensity from global MedTech and diagnostics majors
Mitigation Strategies
- Track record of securing approvals ahead of peers; in-house regulatory team
- Diversified client base across states and PSUs; growing export/private mix
- Phased capex, experienced in-house project execution team
- Cost leadership via in-house manufacturing plus exclusive institutional IP